[IMCAS World 2026 Special] Shaping the Future: K-Medical Aesthetics Leading Innovation ⑤ | Interview with Euncheon Lee, CEO of ViOL
At IMCAS World 2026 in Paris, France, Euncheon Lee, CEO of ViOL, shared the company's global competitiveness in microneedle RF technology and its European market strategy. In January, ViOL obtained EU MDR certification from European notified body TÜV SÜD, establishing a strategic foothold for its European expansion. Exporting to over 70 countries with 'SYLFIRM X' and 'Scarlet,' both developed on the company's proprietary 'NA Effect' technology, ViOL is now expanding its portfolio with MRF device 'CELLINEW' and HIFU device 'DUOTITE,' signaling its evolution into an integrated EBD platform company. Discover the strategy of ViOL as it builds global trust through clinical evidence and regulatory certification.
#MedicalAestheticNews #IMCAS2026 #IMCAS #KMedicalAesthetics #ViOL #SYLFIRMX #CELLINEW #DUOTITE
★ Article Link: https://www.aestheticnews.co.kr/news/articleView.html?idxno=11191

Comments
Post a Comment